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Abstract
Background: Lung inflammation in COPD is poorly controlled by inhaled corticosteroids (ICS). Strategies to
improve ICS efficacy or the search of biomarkers who may select those patients candidates to receive ICS in COPD
are needed. Recent data indicate that MUC1 cytoplasmic tail (CT) membrane mucin can mediate corticosteroid
efficacy in chronic rhinosinusitis. The objective of this work was to analyze the previously unexplored role of MUC1
on corticosteroid efficacy in COPD in vitro and in vivo models.
Methods: MUC1-CT expression was measured by real time PCR, western blot, immunohistochemistry and
immunofluorescence. The inflammatory mediators IL-8, MMP9, GM-CSF and MIP3α were measured by ELISA.
The effect of MUC1 on inflammation and corticosteroid anti-inflammatory effects was measured using cell
siRNA in vitro and Muc1-KO in vivo animal models.
Results: MUC1-CT expression was downregulated in lung tissue, bronchial epithelial cells and lung neutrophils
from smokers (n = 11) and COPD (n = 11) patients compared with healthy subjects (n = 10). MUC1 was correlated with
FEV1% (ρ = 0.7479; p < 0.0001) in smokers and COPD patients. Cigarette smoke extract (CSE) decreased the expression
of MUC1 and induced corticosteroid resistance in human primary bronchial epithelial cells and human neutrophils.
MUC1 Gene silencing using siRNA-MUC1 impaired the anti-inflammatory effects of dexamethasone and reduced
glucocorticoid response element activation. Dexamethasone promoted glucocorticoid receptor alpha (GRα) and
MUC1-CT nuclear translocation and co-localization that was inhibited by CSE. Lung function decline and inflammation
induced by lipopolysaccharide and cigarette smoke in Muc1 KO mice was resistant to dexamethasone.
Conclusions: These results confirm a role for MUC1-CT mediating corticosteroid efficacy in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory, progressive and debilitating lung
disease. It is a major cause of chronic morbidity, the fourth
leading cause of death worldwide and is projected to be
the third leading cause of death by 2020 [1]. The primary
cause of COPD is chronic exposure to cigarette smoke,
which leads to airway inflammation and remodeling, thus
increasing airflow limitation. In contrast with the magni-
tude of COPD, therapeutic options remains limited, and
none of the available drugs have demonstrated to reduce
lung function decline and mortality. The current first-line
maintenance treatment for COPD involves the use of
bronchodilators, including long-acting muscarinic antago-
nists (LAMAs) and long-acting beta 2 agonists (LABAs).
Combination treatment with LAMA and LABA improves
respiratory function, reduces symptoms and exacerbations
compared to monotherapy or inhaled corticosteroids
(ICS)/LABA combinations. Anti-inflammatory options for
COPD are limited to corticosteroids and phosphodiester-
ase 4 inhibitors. While inhaled corticosteroids (ICS) have
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shown good activity in asthma, they are much less effective
in improving lung function and have little or no effect on
controlling the underlying chronic inflammation in COPD
patients [2]. Triple therapy based on ICS in combination
with LABAs and LAMAs is indicated in severe COPD at
risk of exacerbations [3], however the use of ICS is under
debate and needs more evidence to adequately select the
COPD phenotype that takes advantage of this
combination.
The loss of corticosteroid anti-inflammatory efficacy is a
characteristic feature in COPD patients. Several molecular
mechanisms of corticosteroid resistance have now been
identified involving phosphorylation and modifications of
glucocorticoid receptor (GR), and loss of histone
deacetylase-2 (HDAC2) activity/ expression between others
[4]. In patients with corticosteroid resistance, alternative
anti-inflammatory treatments are being investigated as well
as drugs that may reverse the molecular mechanisms of
glucocorticoid resistance. Therefore, the understanding of
corticosteroid resistant mechanisms, as biomarkers of
therapeutic response, could be of potential value to
individualize COPD therapy.
Mucin 1 (MUC1) is a member of membrane-bound
mucins that has been associated with airway epithelial
anti-inflammatory effects through the inhibition of bac-
teria and virus activation of toll-like receptors (TLR)-2–9
[5–8]. The MUC1 protein acts as a membrane receptor
comprising two polypeptide subunits: an N-terminal
extracellular subunit and a C-terminal subunit. A highly
conserved cytoplasmic tail (CT) in the C-terminal subunit
modulates multiple intracellular signals [9] implicated in
different cellular processes such as cellular adherent junc-
tion maintenance and morphogenesis [10]. In COPD,
MUC1-CT dysregulation promotes the loss of bronchial
epithelial barrier integrity [11]. There are several intracel-
lular mediators that can interact with MUC1-CT. Recent
data published by our group indicate that MUC1-CT is
downregulated in patients with chronic rhinosinusitis with
nasal polyps who did not respond to systemic corticoste-
roids [12]. In vitro studies demonstrated that MUC1-CT
forms a complex with GR in response to corticosteroids,
mediating the nuclear complex translocation and the in-
duction of anti-inflammatory gene expression. Although
MUC1 could be a potential biomarker of corticosteroid
response, currently there is no evidence on the association
of the lack of MUC1-CT expression and corticosteroid
resistance in COPD. The present work analyzes the
association of MUC1-CT with corticosteroid efficacy
using multiple approaches, including translational, cellular
in vitro and animal in vivo models.
Materials and methods
Unless stated otherwise, all reagents used were obtained
from Sigma Chemical Co. (Madrid, Spain).
Patients
Sputum neutrophils, peripheral blood neutrophils and bron-
chial epithelial cells were obtained from COPD patients,
healthy smokers and healthy non-smoker subjects. Clinical
characteristics of patients are defined in Table 1.
Twenty-two patients with COPD, defined according to Glo-
bal Initiative for Chronic Obstructive Lung Disease (GOLD)
2013 guidelines, were enrolled in this study. Patients were
aged 67.5 ± 8 years, had forced expiratory volume in 1 s
(FEV1) of 48.6 ± 8% predicted, and all were prescribed an in-
haled corticosteroid, long-acting anticholinergic and
long-acting beta 2 agonists. All COPD patients were current
smokers and bronchitic. The minimum washout period in
stable COPD patients for sampling sputum or blood was
4 days, which avoided effects of chronic medication on the
results.COPD patients in this study were classified as GOLD
2 (moderate disease; n = 3) and GOLD 3 (severe disease; n
= 19). There were no exacerbations of the disease within
2 weeks prior to taking blood samples. Fifteen age-matched
non-smoking control healthy subjects with normal lung
function (age 66 ± 4 years old, FEV1 98 ± 3% predicted) and
fifteen healthy smokers (age 65 ± 9 years old, FEV1 89 ± 6%
predicted) were also recruited. Routine lung function tests
were performed to evaluate forced vital capacity (FVC),
FEV1 and FEV1/FVC ratio using a Vitalograph® alpha III
spirometer (Vitalograph, Maids Moreton, UK).
Peripheral human lung tissue was obtained from 3
types of subjects (Thoracic Surgery and Pathology Ser-
vices of the University General Consortium Hospital and
University and Polytechnic Hospital La Fe, Spain): A)
Patients with COPD who were underwent surgery for
organ transplantation program (n = 15). B) Lung ex-
plants of non-smoker healthy donor subjects from the
transplant program (were used as controls), without any
lung disease (n = 11). C) Smoker donor subjects with
normal lung function and lung cancer who were under-
going lung surgery for treatment purposes (lung tissue
used in this work was as far as possible of the solitary
cancer lesion; n = 12). Inclusion criteria comprised either
non-smokers or current smokers with or without COPD
who were free of symptoms of upper respiratory tract in-
fection. After selection based on lung function, all lung
tissue samples chosen for the study were checked histo-
logically using the following exclusion criteria: (1) pres-
ence of tumor, (2) presence of post stenotic pneumonia,
and (3) fibrosis of lung parenchyma. This project was
approved by the local ethics committee of General Uni-
versity Hospital, Valencia, Spain, and written informed
consent was taken from each patient or volunteer before
starting blood sampling and lung function testing.
Isolation and culture of primary bronchial epithelial cells
Human bronchial epithelial cells (HBECs) from small
bronchi were isolated as previously outlined [13]. Small
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pieces of human bronchi (0.5–1 mm internal diameter)
were excised from microscopically normal lung areas,
carefully dissected from lung parenchyma and plated on
collagen-coated culture dishes (10 μg/cm2 rat type I col-
lagen; Sigma) in bronchial epithelial growth medium
(BEGM), comprising bronchial epithelial basal medium
(BEBM) supplemented with bovine pituitary extract
(52 μg/ml, hydrocortisone 0.5 μg/ml), human recombin-
ant epidermal growth factor ([EGF] 25 ng/ml), epineph-
rine (0.5 μg/ml), transferrin (10 μg/ml), insulin (5 μg/
ml), retinoic acid (50 nM), triiodo-L-thyronine (6.5 ng/
ml), gentamycin (40 μg/ml), amphotericin B (50 ng/ml),
and bovine serum albumin (1.5 μg/ml). Small bronchi
were oriented with the epithelial layer in contact with
the culture plate. After a period of ~ 1–2 weeks, bronchial
epithelial cells were observed around the bronchi. After
trypsinization (passage 2–4), cells were cultured accord-
ingly for different experiments. All the experiments
performed in this study with primary HBEC were done on
monolayer cultures. The identity of the monolayer as
bronchial epithelial cells was confirmed using morpho-
logical criteria and immunofluorescence for cytokeratin 5
(KRT5) as well as later use of in vitro differentiation in
air-liquid interface as pseudo-stratified bronchial epithe-
lium with basal cells, ciliated cells, columnar, and goblet
cells (data not shown). Cell viability was assessed by vital
trypan blue exclusion analysis using the Countness® auto-
mated cell counter (Life Technologies, Madrid, Spain).
Cell viability was > 98% in all cell cultures.
The bronchial epithelial BEAS2B cell line was obtained
from American Type Culture Collection and cultured in
BEGM media with supplements (Lonza, Madrid, Spain)
on collagen-coated culture dishes (10 μg cm− 2; rat type I
collagen) at 37 °C with 5% CO2 in humidified air. The
culture medium was replaced every 48 h.
Human neutrophil isolation from sputum and peripheral
blood
Neutrophils were isolated from peripheral venous blood
and cultured as previously outlined [14]. using 3% dextran
500 (in 0.9% saline) together with Ficoll-Paque Histopaque
1077 (Amersham Pharmacia Biotech, Barcelona, Spain) at a
ratio of 2:1. The neutrophil preparations were > 97% pure
as assessed by Giemsa staining and had viability of > 99%
as measured by trypan blue exclusion. Neutrophils from
spontaneous sputum (~ 2 ml) were collected and processed
with dithiothreitol using established methods [15]. Sputum
cell pellets were resuspended in RPMI 1640 supplemented
with 10% foetal calf serum, 1% penicillin–streptomycin and
1 mmol L-glutamine/L at a concentration of 1 × 106 cells/
ml. An aliquot containing 4 × 105 cells was incubated on a
24-well plate for 1 h at 37 °C in humidified 5% CO2. Prepa-
rations containing < 95% neutrophils were discarded.
Neither the purity nor the viability of the cell preparations
was affected by the different experimental conditions of the
study.
Preparation of cigarette smoke extract solutions
Cigarette smoke extract (CSE) was prepared as previ-
ously outlined [16]. Briefly, the smoke of a research
cigarette (2R4F; Tobacco Health Research, University of
Kentucky, KY, USA) was generated by a respiratory







Age, yr. (mean (SD) 66 ± 4 65 ± 9 67.5 ± 8
Sex (M/F) 11/4 12/3 17/5
Tobacco consumption, pack-yr 0 24.1 ± 6 30.5 ± 8
FEV1, % pred 98 ± 3 89 ± 6 48.6 ± 8*
FVC, % pred 91 ± 2 90 ± 4 91.5 ± 6
FEV1/FVC % 94 ± 5 88 ± 1 61.2 ± 10*
GOLD 1 (mild) patients, no. 0 0 0
GOLD 2 (moderate) patients, no. 0 0 3
GOLD 3 (severe) patients, no. 0 0 19
GOLD 4 (very severe) patients, no. 0 0 0
Receiving inhaled steroids, no. 0 0 22
Receiving theophyllines, no. 0 0 0
Receiving long-acting b2-agonist, no. 0 0 22
Receiving anticholinergics, no. 0 0 22
Total peripheral blood neutrophils 4.2 ± 0.6 × 109/L 6.5 ± 0.9 × 109/L* 9.5 ± 2.1 × 109/L*
COPD Chronic obstructive pulmonary disease, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity; Pack-yr = 1 year smoking 20 cigarettes-day. % pred,
% predicted. Data are mean ± SDs. * P < 0.05 related to Healthy subjects
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pump (Apparatus Rodent Respirator 680; Harvard,
Germany) through a puffing mechanism similar to the hu-
man smoking pattern (3 puffs/min; 1 puff volume of
35 ml; each puff duration lasting 2 s with 0.5 cm above
the filter) and was bubbled into a flask containing 25 ml
of pre-warmed (37 °C) Roswell Park Memorial Institute
(RPMI)-1640 culture medium. The CSE solution was ster-
ilized by filtration through a 0.22 μm cellulose acetate
sterilizing system (Corning, USA). The resulting CSE solu-
tion was considered 100% CSE and was used within
30 min of preparation. CSE 10% approximately corre-
sponds to the exposure associated with smoking of two
packs per day [17]. The quality of the prepared CSE solu-
tion was assessed based on the absorbance at 320 nm,
which is the specific light absorption wavelength of perox-
ynitrite. Stock solutions with an absorbance value of 3.0 ±
0.1 were used. To test for cytotoxicity and apoptosis due
to CSE, bronchial epithelial cells were treated with CSE
concentrations of up to 10% for 24 h. No significant differ-
ences in the lactate dehydrogenase supernatant level
(lactate dehydrogenase cytotoxicity assay; Cayman, Spain)
or in the number of apoptotic cells (annexin V-FITC)
were observed in comparison with the control group [18].
Histology and immunofluorescence analysis
Lung histology was conducted as previously reported in
the smoking animal model [19]. Tissue blocks (4 μm
thickness) were stained with haematoxylin-eosin for
assessment of the inflammatory lung infiltration. Im-
munofluorescence of MUC1-CT and GRα were analyzed
in bronchial epithelial cell cultures and in bronchial
epithelium from animals.
The in vitro cell culture of human bronchial epithelial
cells was fixed (4% paraformaldehyde, 30 min, at room
temperature) after appropriate treatments. Cells were
permeabilized (20 mM HEPES at pH 7.6, 300 mM sucrose,
50 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100), blocked
(10% goat serum in PBS), and incubated with the primary
antibodies MUC1-CT (rabbit anti-human polyclonal
MUC1-CT antibody (Novus Biologicals (NBP1–60046))
and GRα (mouse anti-human monoclonal glucocorticoid
receptor α antibody (GRα; BD Biosciences (611227)) over-
night at 4 °C, followed by secondary antibody anti-rabbit/
mouse rhodamine/FITC- (1:100, Molecular Probes). Cell
nuclei were marked with 49–6-diaidino-2-phenylindole
dihydrochloride (1:10,000; DAPI).
Mouse lung tissue was fixed in paraformaldehyde (4%)
for 48 h and embedded in Tissue-Tek® OCT™ cryosection-
ing compound (Sakura Finetek Europe BV, Leiden). Blocks
were cut into 10 μm thick sections, permeabilized in Tri-
ton X 100 (0.1% in PBS) for 5 min, blocked in 10% goat
serum in PBS and co-immunostained with MUC1-CT and
GRα antibodies for 24 h at 4 °C followed by a secondary
FITC or rhodamine conjugated anti-mouse/rabbit IgG
antibody and finally DAPI (2 μg/ml) to mark nuclei
(Molecular Probes, Leiden, The Netherlands).
Colocalization of MUC1-CT and GRα was performed
using a confocal spectral Leica TCS SP2 microscope with
× 1000 magnification and 3× zoom. Red (HeNe 543 nm),
green (HeNe 488 nm), and blue (Ar 351 nm, 364 nm) la-
sers were used. Colocalization studies were performed
using the Leica confocal software v2.61.
Cell stimulations and IL-8, GM-CSF, MIP3a and MMP-9
assays
Primary HBECs or isolated human neutrophils from
non-smoker, smoker, and smokers with COPD were ad-
justed to 500 × 106 cells per well in 6-well plates and incu-
bated in BEGM culture medium at 37 °C with 5% CO2.
Cells were then treated in the presence or absence of
dexamethasone (0.1 nM-1 μM; Sigma Aldrich, Madrid,
Spain), for 1 h. After drug incubation, HBECs or neutro-
phils were stimulated with the TLR4 agonist lipopolysac-
charide (LPS) (Invivogene, Toulouse, France) at 1 μg/ml
final concentration alone or in combination with CSE at
the indicated times as previously outlined [12, 20].
In additional experiments, scrambled siRNA control or
MUC1 gene-targeted siRNA were transfected to Beas2B
cells for 48 h. Cells were then incubated with dexametha-
sone 1 μM for 1 h and stimulated with/ without CSE.
Supernatants were collected and centrifuged at 120 g
for 5 min. IL-8, GM-CSF, MIP3α or MMP9 were mea-
sured in cell-free supernatants using commercially avail-
able enzyme-linked immunosorbent assay kits (R&D
Systems, Nottingham, UK).
Real-time RT-PCR and siRNA experiments
Total RNA was isolated from HBECs, human neutrophils,
human and animal lung tissue using TriPure® Isolation Re-
agent (Roche, Indianapolis, USA). The integrity of the ex-
tracted RNA was confirmed with Bioanalyzer (Agilent, Palo
Alto, CA, USA). Reverse transcription was performed in
300 ng of total RNA with a TaqMan reverse transcription
reagents kit (Applied Biosystems, Perkin-Elmer Corpor-
ation, CA, USA). cDNA was amplified with specific primers
and probes predesigned by Applied Biosystems for TLR4
(Hs00152939_m1), MUC1 (Hs00159357_m1) and MKP1
(Hs00610256_g1) for human samples, and MUC1 (Mm0
0449604_m1), GRα (Mm00449604_m1), MKP1 (Mm004
57274_g1), CD200 (Mm00487740_m1), RGS2 (Mm00
501385_m1), TSC22D3 (Mm00726417_m1), IL-8 (Mm042
08136_m1), IL-13 (Mm99999190_m1) and CRISPLD
(Mm01240812_m1) for mouse samples in a 7900HT Fast
Real-Time PCR System (Applied Biosystems) using Univer-
sal Master Mix (Applied Biosystems).
MKP1 is a mitogen-activated protein kinase phosphat-
ase whose expression is increased by corticosteroids and
induces the degradation/ de-phosphorylation of several
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kinases such as ERK1/2 and p38, thus increasing the
anti-inflammatory properties of corticosteroids [21].
RGS2 is a GTPase-activating protein that switches off
signaling from Gq-linked G protein-coupled receptors
(GPCRs). In airway smooth muscle, RGS2 is upregulated
in a positive cooperative manner by glucocorticoid and
LABA, and exerts a bronchoprotective effect; in epithe-
lial and other cells RGS2 expression may attenuate pro-
inflammatory mediator release [22].
TSC22D3 is a glucocorticoid-inducible gene that in-
hibits the transcriptional activity of both NF-kB and
AP-1. Glucocorticoid-induced TSC22D3 expression may
also be modestly enhanced by LABAs. It is reported that
induction of this gene suppresses various indices of in-
flammation [23].
Previously known to mediate several other functions,
CRISPLD2 was recently found to encode as a novel, se-
creted, mammalian LPS binding protein in both humans
and mice. Enhancement of fluticasone propionate in-
duced CRISPLD2 expression could contribute to the re-
duction in exacerbations in COPD produced by
infections with gram-negative bacteria by downregulat-
ing TLR4-mediated proinflammatory responses [24].
CD200 is a glucocorticoid-inducible gene. Pulmonary
alveolar macrophages have high constitutive expression
of CD200R. Signaling through this receptor involves the
interaction of CD200R-bearing cells with other cells
(e.g., airway epithelia) that express CD200. Studies in
mice have shown that the CD200/CD200R interaction
blunts macrophage activation measured as proinflamma-
tory cytokine generation. Acute exacerbations of COPD
are triggered, primarily, by prolonged bouts of excessive
inflammation in response to bacterial and viral infections.
Pharmacological upregulation of CD200 on epithelial and
other airway cells in COPD could attenuate inflammation
and reduce exacerbation frequency [25].
Expression of the target gene was expressed as the fold
increase or decrease relative to the expression of human
GAPDH (4310884E) or mouse GAPDH (4352339E) as
an endogenous control (Applied Biosystems). The mean
value of the replicates for each sample was calculated
and expressed as the cycle threshold (Ct). The level of
gene expression was then calculated as the difference
(ΔCt) between the Ct value of the target gene and the Ct
value of GAPDH. The fold changes in the target gene
mRNA levels were designated 2-ΔCt.
Small interfering RNA (siRNA), including the scrambled
siRNA control, was purchased from Ambion (Hunting-
don, Cambridge, UK). MUC1 gene-targeted siRNA (iden-
tification no. 4392420) was designed by Ambion. Beas2b
cells were transfected with siRNA (50 nM) in serum and
antibiotic-free medium. After 6 h, the medium was aspi-
rated and replaced with medium containing serum for a
further 42 h before cell stimulation. The transfection
reagent used was lipofectamine-2000 (Invitrogen, Paisley,
UK) at a final concentration of 2 μg/ml.
Western blotting analysis
Western blotting analysis was used to detect changes in
lung tissue expression of MUC1-CT, TLR-4, phospho-
ERK1/2, MKP1, GRα and phospho-GR-Ser226, phos
pho-p38. Lung tissue from human and mouse were ho-
mogenized and lysed on ice with a lysis buffer compris-
ing a complete inhibitor cocktail plus 1 mM ethylen
ediaminetetraacectic acid (Roche Diagnostics Ltd., West
Sussex, UK) with 20 mM Tris base, 0.9% NaCl, 0.1% Tri-
ton X-100, 1 mM dithiothreitol, and 1 mg/mL pepstatin
A. The Bio-Rad assay (Bio-Rad Laboratories Ltd., Herts,
UK) was used according to the manufacturer’s instruc-
tions to quantify the level of protein in each sample to
ensure equal protein loading. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis was used to separate
the proteins according to their molecular weight. Briefly,
15 μg of proteins (denatured) along with a molecular
weight protein marker (Bio-Rad Kaleidoscope marker;
Bio-Rad Laboratories) were loaded onto an acrylamide
gel consisting of a 5% acrylamide stacking gel stacked on
top of a 10% acrylamide resolving gel and run through
the gel by application of 100 V for 1 h. Proteins were
transferred from the gel to a polyvinylidene difluoride
membrane using a wet-blotting method. The membrane
was blocked with 5% Marvel in PBS containing 0.1%
Tween20 (PBS-T), probed with polyclonal MUC1-CT
antibody (Novus Biologicals (NBP1–60046)), monoclonal
phospho-ERK1/2 (Sigma-Aldrich (M9692)), monoclonal
TLR4 antibody (Novus Biologicals (H00007099-M02)),
monoclonal glucocorticoid receptor α antibody (GRα; BD
Biosciences (611227)), monoclonal phospho-GR-Ser226
antibody (Novus Biologicals (NB100–92540)), polyclonal
Mitogen Activated Protein Kinase Phosphatase 1 antibody
(MKP1) (Assay Biotech (B1099), and monoclonal
phospho-p38 antibody (Cell Signaling (4511)), and nor-
malized to total mouse anti-human β-actin antibody
(monoclonal antibody, catalog no. A1978; Sigma). The en-
hanced chemiluminescence method of protein detection
using enhanced chemiluminescence reagents (ECL Plus;
Amersham GE Healthcare, Buckinghamshire, UK) was
used to detect labeled proteins. Densitometry of films was
performed using the Image J 1.42q software (available at
http://rsb.info.nih.gov/ij/, USA). Results of target protein
expression are expressed as the percentage of the densi-
tometry of the endogenous controls β-actin.
Immunoprecipitation
Equal amounts of protein (200 μg) were incubated with
2 μg of anti-GRα or anti-MUC1-CT antibodies and the
IgG isotype control. The immune complexes were pre-
cipitated with protein G on Sepharose 4B fast flow beads
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(Sigma (P-3296)) overnight at 4 °C. After washing three
times with NET buffer containing 50 mM Tris-HCl at
pH 8.0, 150 mM NaCl, and 0.1% Nonidet P-40, the
bound materials were eluted from the immunoprecipi-
tates in reducing SDS-PAGE loading buffer containing
10% SDS, 1 M Tris-HCl at pH 6.8, 50% glycerol, 10%
2-mercaptoethanol, and 2% bromophenol blue at 100 °C
for 10 min. Immunoprecipitated protein complexes were
assayed by western blotting as described above and
probed using anti-GRα or anti-MUC1-CT antibodies, as
appropriate.
Glucocorticoid response element transfection assay
Beas2B epithelial cells were seeded (40.000 cells/well)
and cultured for 24 h under a 5% CO2/air atmosphere at
37 °C in 96-well plates containing Dulbecco’s modified
Eagle’s Medium (DMEM). The Cignal GRE Reporter
Assay Kit (QIAGEN, Cat no. 336841) was used to moni-
tor the activity of glucocorticoid receptor-induced signal
transductions pathways in cultured cells, following the
manufacturer’s indications. First, cells were transfected
with MUC1 gene-targeted siRNA or scrambled siRNA
control as described above. 24 h later, cells were trans-
fected with Cignal Reporter (100 ng), Cignal negative
control (100 ng) and Cignal positive control (100 ng) in
Opti-MEM serum-free culture medium using Lipofecta-
mine 2000 Reagent (Invitrogen) as transfection reagent.
Subsequently, cells were incubated with the transfection
reagents at 37 °C in a 5% CO2 incubator for 16 h. After
this incubation period, cells were pre-incubated during
6 h with different dexamethasone concentrations
(0.1 nM-1 μM) in DMEM.
After this 6 h period, the luciferase assay was devel-
oped by using Dual-Luciferase Reporter Assay System
(Promega, Cat N° 1910) following the manufacturer’s
protocol for developing the assay. In brief, growth
medium was removed from the cultured cells and the
surface of the cultured cells was washed gently with
phosphate buffered saline (PBS). After removing com-
pletely the rinse solution, Passive Lysis Buffer 1X was
added. The culture plate was then placed on an orbital
shaker, with gentle shaking at room temperature for
15 min. In the meantime, Luciferase Assay Reagent II
(LAR II) was prepared by resuspending the provided
lyophilized Luciferase Assay Substrate in 10 mL of the
supplied Luciferase Assay Buffer II. A volume of 100 μl
of LAR II was predispensed in the appropriate number
of wells of a white 96-well plate. Then, a volume of 20 μl
of cell lysate was added into the wells containing LAR II,
and mixed by pipetting 2 or 3 times. The white plate
was placed in the luminometer (Victor), reading was ini-
tiated and the Firefly luciferase activity was measured. In
the meantime, the Stop & Glo Reagent was prepared,
just before use, by diluting 1 volume of the Stop & Glo
Substrate to 50 volumes of Stop & Glo Buffer. Following
the first measure, 100 μl of Stop & Glo Reagent was
dispensed in the corresponding wells. The plate was
replaced in the luminometer and a second reading was
initiated and the Renilla Luciferase activity was recorded.
Data are expressed as 2xGRE fold induction of luciferase
relative to unstimulated cells.
Inflammatory cigarette smoke animal model
Experimentation and handling were performance in
accordance with the guidelines of the Committee of Ani-
mal Ethics and Well-being of the University of Valencia
(Valencia, Spain). The animal studies followed the AR-
RIVE guidelines [26]. Mice studies used pathogen-free
female C57BL/6 of 12 weeks years old (Harlan Iberica®,
Barcelona, Spain). Muc1-KO mice C57BL/6 animals
were originally generate by Sandra Gendler (Mayo
Clinic, NY, USA) [27] and donated by the animalerie
Institut de Médecine Prédictive et de Recherche Théra-
peutique, (Lille Cedex, France). Mice were housed with
free access to water and food under standard conditions:
relative humidity 55 ± 10%; temperature 22 ± 3 °C; 15 air
cycles/ per hour; 12/12 h Light/Dark cycle.
The experimental procedure started at day 0 with the
basal measure of micro-computed tomography (CT)
coupled to positron emission tomography (PET) lung
image analysis (micro-CT-PET Albira Imaging System
(Oncovision®, Spain) and measure of lung function by
plethysmography of whole body (Miami, Florida, USA). At
day 1 intranasal lipopolysaccharide (LPS from Salmonella
Typhimurium, Sigma Aldrich, Madrid, Spain) or vehicle
(sterile deionized water) was administered at 75 μg in
25 μl as previously outlined to induce an inflammatory re-
sponse [28]. Between days 2 to day 3, mice were exposed
to cigarette smoke of 6 cigarettes (2R4F; Tobacco Health
Research, University of Kentucky, KY, USA). Between day
4 and day 5 mice were exposed to cigarette smoke of 8
cigarettes. The last day of procedure (day 6), mice were
exposed to cigarette smoke of 10 cigarettes, and anlaysis
of micro-CT-PET and lung function were assessed. Each
cigarette exposure was programed to be consumed in
5 min followed by 8 min of airway exposure using a flux
of 5 L/min [29]. A nose only system (TSE systems, Bad
Homburg, Germany) was employed for cigarette smoking.
Each drag had 1.9 s, and the period of time between drags
was 20 s. Control animals received same conditions inhal-
ing air instead of cigarette smoke. Dexamethasone was
given at 10 mg/kg/day and 3 mg/kg/day in methocel 10%
suspensions, once daily, p.o. by gavage in a volume of
10 mL/kg, starting at day 1 until day 6 of the experimental
procedure. Dexamethasone was administer 1 h before
cigarette smoke exposure. The account for experimental
groups was estimated in a number of 8 mice (n = 8) based
in previous findings [29]. The primary outcome was the
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50% reduction of the lung inflammation (SUV) by dexa-
methasone 3 mg/kg/day. The sample size was calculated
for an effect size f of 1.8, α error of 0.05 and power of
0.96, using one tailed analysis of variance (ANOVA).
Different experimental groups were assigned as follow:
1) Intranasal sterile deionized water + airway nose only
system exposure (n = 8); 2) Intranasal sterile deionized
water + airway nose only system exposure + dexametha-
sone 10 mg/kg/day (n = 8); 3) Intranasal LPS + airway nose
only system exposure (n = 8); 4) Intranasal LPS + cigarette
smoke nose only system exposure (n = 8); 5) Intranasal
LPS + cigarette smoke nose only system exposure + dexa-
methasone 10 mg/kg/day (n = 8); 6) Intranasal LPS +
cigarette smoke nose only system exposure + dexametha-
sone 3 mg/kg/day (n = 8); 7) Intranasal LPS + airway nose
only system exposure + 10 mg/kg/day (n = 8); 8) Intranasal
LPS + airway nose only system exposure + 3 mg/kg/day.
Micro-CT-PET analysis
The animal images were acquired at day 0 and 6 using
the multimodal micro-PET-CT system (micro-CT-PET
Albira Imaging System (Oncovision®, Spain). Animals
were anesthesized with intraperitoneal mixture of keta-
min (70 mg/Kg) and medetomidin (0.25 mg/kg). After
10 min of stabilization animals were injected intraperito-
neally with 300 μCi.
fludeoxyglucose 18F (18F-FDG). After 30 min, the ani-
mals were allocated in supine position in a cradle made
of plexiglas to acquire micro-CT and PET images.
Acquisitions of both PET and CT were made with an off-
set of 10 mm in length to visualize the lung region. Acquisi-
tion by CT (Carestream Molecular Imaging, Woodbridge,
CT) was performed with good acquisition quality, high
dose (400 μA) and high voltage (45Kv) with the Step &
Shoot acquisition mode and FBP reconstruction algorithm
(Filtered Back Projection). In the PET mode, the studies
were programmed with a field of vision (Field Of View
(FOV)) of 80 mm, an acquisition time of 90 s per projection
during 15 min. The images were reconstructed using the
OSEM Cross algorithm with a number of iterations of 3
using the standard reconstruction parameters of the Albira
Suite 5.0 Reconstructor software. The images were analyzed
and quantified using the PMOD analysis software version
3.2 (PMOD Technologies LTD, Zurich, Switzerland). Once
acquired, the PET / CT images were reconstructed and
merged.
Volumes of interest (VOI) of the lung region were de-
termined for the CT images. The VOI was analyzed for
each subject for their different days of acquisition. For
PET images, the VOI obtained in the CT image of each
subject was taken as a template and it was extrapolated to
the PET image and subsequently quantified. The quantifi-
cation of images provided the number of accounts ac-
quired per pixel unit. This value was relativized by the
dose injected and by subject weight, resulting in the stand-
ard uptake value (SUV).
Statistical analysis
Statistical analysis of results was carried out by paramet-
ric (animal and cellular studies) or non-parametric (hu-
man tissue studies) analysis as appropriate. P < 0.05 was
considered statistically significant. Non-parametric tests
were used to compare results from human samples of
control patients, smoker and COPD patients. In this
case, data were displayed as medians and interquartile
range values. When the comparisons concerned more
than two groups, analysis of variance (Kruskal-Wallis
test) was first performed. In the case of a global signifi-
cant difference, between-group comparisons were
assessed by the Dunn’s post-hoc test, which generalizes
the Bonferroni adjustment procedure. When the com-
parisons concerned only 2 groups, between-group differ-
ences were analyzed by the Mann Whitney test. Results
from animal and cellular in vitro mechanistic cell experi-
ments were expressed as mean ± SE of n experiments
since normal distribution for each data set was con-
firmed by histogram analyses and Kolmogorov–Smirnov
test. In this case, statistical analysis was carried out by
parametric analysis. Two-group comparisons were ana-
lysed using the two-tailed Student’s paired t-test for
dependent samples, or unpaired t-test for independent
samples. Multiple comparisons were analysed by
one-way or two-way analysis of variance followed by
Bonferroni post hoc test. Variable correlations were im-
plemented using spearman ρ analysis.
Results
MUC1 expression is decreased in lung tissue from
smokers and COPD patients
Lung tissue, bronchial epithelial cells and neutrophils were
isolated from healthy, current smokers and COPD pa-
tients based in the clinic characteristic described in Table
1. The gene mRNA expression of MUC1 decreased from
143 (2-ΔCt) in healthy lung tissue to 15 (2-ΔCt) and 4
(2-ΔCt) in lug tissue from smokers and COPD patients
respectively (Fig.1a). Similar results were observed in
bronchial epithelial cells and sputum neutrophils from
smokers and COPD patients (Fig. 1b, c). In the same way,
MUC1-CT protein expression was down-regulated in lung
tissue from smokers and COPD patients to a 65 and 30%
of control respectively (Fig. 1d). The MUC1-CT expres-
sion showed the same pattern of MUC1-CT distribution
in lung tissue from healthy, smoker and COPD patients
(data not shown), mainly located in bronchial epithelial
cells and alveolar type II cells as previously described [30].
TLR4 mRNA expression was significantly upregulated in
lung tissue, bronchial epithelial cells and sputum neutro-
phils from smokers and COPD patients (Fig. 1e-g), while
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TLR4 protein expression only reach significant differences
in COPD patients (Fig. 1h). The expression of MUC1 and
TLR4 in lung tissue from smokers and COPD patients
was inversely correlated (ρ = − 0.587; P = 0.0051; Fig. 1i).
The FEV1% of smokers and COPD patients was directly
correlated with MUC1 lung tissue expression (ρ = −
0.7479; P < 0.0001; Fig. 1j).
Corticosteroid anti-inflammatory effects are impaired in
cells from smokers and COPD patients stimulated with
cigarette smoke
Cigarette smoke extract (CSE) dose-dependently de-
creased MUC1 expression in primary bronchial epithe-
lial cells (HBECs) from healthy subjects reaching 73%
inhibition at 10% CSE concentration (Fig. 2a). Dexa-
methasone 1 μM inhibited the LPS-induced IL-8,
GM-CSF and MIP3α to 98, 82 and 48% of inhibition re-
spectively (Fig. 2b-d). Similar findings were observed
when CSE 5% was used as stimulus (Fig. 2b-c). In
contrast, HBECs stimulated with the LPS and CSE com-
bination were resistant to the anti-inflammatory effects
of dexamethasone on the IL-8, GM-CSF and MIP3α re-
lease (Fig. 2b-e). HBECs from COPD showed higher
IL-8 levels than cells from smokers and healthy subjects
in response to LPS and CSE (Fig. 2f ). Dexamethasone
showed more %maximum inhibitory effect (%Emax) on
IL-8 release in HBECs from healthy subjects (%Emax
60%) compared with cells from smokers (%Emax 24.5%)
and COPD patients (%Emax 21.2%) (Fig. 2g).
CSE dose-dependently decreased MUC1 expression in
sputum neutrophils, reaching 96% of inhibition after
CSE 10% exposure (Fig. 3a). Similar results were ob-
served in neutrophils from peripheral blood (data not
shown). LPS and CSE increased IL-8 and MMP9 release
in cultured peripheral blood neutrophils which was
significantly higher in neutrophils from COPD patients
(Fig. 3b-d). Dexamethasone showed impaired
anti-inflammatory effects on the LPS and CSE-induced
Fig. 1 MUC1 downregulation and TLR4 overexpression in lung tissue from heavy smokers and COPD patients. Lung tissue from healthy (n = 10),
smokers (n = 11) and COPD patients (n = 13) were analysed. MUC1 mRNA gene expression in lung tissue homogenates (a), bronchial epithelial
cells (b) and sputum neutrophils (c). d MUC1-CT protein expression in lung homogenates.TLR4 mRNA gene expression in lung tissue
homogenates (e), bronchial epithelial cells (f) and sputum neutrophils (g). h MUC1-CT protein expression in lung homogenates. i Correlation of
TL4 and MUC1 gene expression in lung tissue from smokers and COPD patients. j Correlation of FEV1% and MUC1 gene expression in lung tissue
from smokers and COPD patients. Gene expression was analyzed by real time PCR using the 2-ΔCt as described in methods. Protein expression
was analyzed by western blot. Representative western blot are showed. Data are presented as median with interquartile range. “P” exact values
were obtained following Kruskal Wallis test. FEV1%: forced expiratory volume in 1 s
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IL-8 and MMP9 release, in neutrophils from smokers
and COPD patients (Fig. 3f-i).
MUC1 mediates corticosteroid anti-inflammatory effects
in vitro
Beas2b bronchial epithelial cells transiently transfected
with siRNA-MUC1 were resistant to the effects of dexa-
methasone which did not increase the anti-inflammatory
MKP1 and MUC1 expression (Fig. 4a, b). In the same way,
in transiently transfected Beas2b cells with siRNA-MUC1,
dexamethasone did not reduce IL-8 and GM-CSF release
in response to CSE (Fig. 4c, d). Corticosteroids mediate
part of its anti-inflammatory effects through transactiva-
tion of genes that encode proteins with anti-inflammatory
properties, such as MKP1, via direct interaction of the
agonist-bound GR to glucocorticoid response elements
(GREs). In this work, cells were transfected with GRE
reporter construct in siRNA-MUC1 cells and siRNA(−)
cells and incubated with dexamethasone 1 μM during 4 h.
Treatment of 2xGRE Beas2B reporter cells with
dexamethasone (0.1 nM to 1 μM) for 4 h induced GRE
dependent transcription in a concentration-dependent
manner that was significantly lower in siRNA-MUC1 than
in siRNA(−) control cells (Fig. 4e).
Confocal immunofluorescence for GRα and MUC1-
CT revealed that both proteins are co-expressed in the
cytoplasm of primary HBECs around the nucleus. After
dexamethasone addition the GRα-MUC1-CT complex
was translocated to the cell nucleus. However,
pre-treated cells with CSE 5% for 24 h decreased
MUC1-CT expression and blocked GRα-MUC1-CT nu-
cleus translocation (Fig. 4f ). HBECs incubated with
CSE5% for 24 h showed a decreased expression of
MUC1-CT, and an increased expression of GR phos-
phorylated at serine 226 (GR-Ser226), p-ERK1/2 and
p-P38 expression (Fig. 4g). The proteasomal inhibitor
MG-132 5 μM inhibited the loss of expression of
MUC1-CT induced by CSE5% and reversed the increase
of GR-Ser226 (Fig. 4h). Immunoprecipitation experi-
ments revealed that MUCI-CT forms a complex with
GRα that is dissociated by CSE in a concentration-
dependent manner (Fig. 4i). The incubation of HBECs
Fig. 2 Cigarette smoke mediates corticosteroid resistance and decreases MUC1 expression in human bronchial epithelial cells (HBEC). a Cigarette
smoke extract (CSE) decreased the mRNA gene expression of MUC1 in HBEC from healthy subjects. b-e HBECs stimulated with lipopolysaccharide
(LPS) and CSE 5% were resistant to the anti-inflammatory effects of dexamethasone on IL-8, GM-CSF and MIP3α release. f Both LPS and CSE
induce higher IL-8 release in HBECs from smokers and COPD patients than in cells from healthy subjects. g Dexamethasone shows lesser
inhibitory effect on LPS-induced IL-8 release in cells from smokers and COPD patients than in cells from healthy subjects. The results are shown
as mean ± SE of n = 4 cell populations from healthy subjects (a-g), smokers (f, g) and COPD (f, g) patients. Gene expression was analyzed by real
time PCR using the 2-ΔCt as described in methods. Two-way ANOVA followed by Bonferroni post-hoc tests. a, b, d and e *P < 0.05 compared with
control; #P < 0.05 compared with stimulus. (c) *P < 0.05 compared with CSE+ LPS group. f *P < 0.05 compared with non-smoker group; #P < 0.05
compared with control group; ┴ P < 0.05 compared with smoker group. g *P < 0.05 compared with non-smoker group; #P < 0.05 compared with
smoker group
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with CSE 5% during 24 h prevented the formation of
GRα-MUC1-CT complex induced by dexamethasone
(Fig. 4j).
MUC1 mediates corticosteroid anti-inflammatory effects
in vivo
Dexamethasone administered at 3–10 mg/kg/day orally
improved respiratory resistance (enhanced pause
(Penh)), decreased inflammatory cells (Additional file 1:
Data S1A-D), and IL-8/IL-13 (Additional file 1: Data
S2A and S2B) in bronchoalveolar lavage (BAL) fluid of
WT control animals treated with LPS and in a lesser ex-
tent in LPS + CS treated animals. In Muc1 KO animals,
dexamethasone did not improve Penh neither number of
inflammatory cells nor IL8/IL13 cytokines in BAL fluid
(Additional file 1: Data S1 and S2). Muc1 KO mice
showed predominant neutrophil inflammation after LPS
or LPS + CS exposure (Additional file 1: Figure S1). Lung
hematoxylin & eosin histology showed lesser lung in-
flammatory cell infiltrates in lung sections from WT ani-
mals treated with dexamethasone in both groups:
animals exposed to LPS and LPS + CS (Additional file 1:
Figure S3). In contrast, dexamethasone did not reduced
inflammatory cell infiltrates in Muc1 KO animals (Add-
itional file 1: Figure S3).
In lung tissue, LPS and LPS + CS administration in-
creased IL-8 and IL-13 mRNA expression (Fig. 5a, b).
Dexamethasone inhibited IL-8 and IL-13 expression only
in WT animals stimulated with LPS (P < 0.05) but not in
animals stimulated with LPS + CS (Fig. 5a, b). In Muc1
KO mice dexamethasone did not inhibited IL-8 and IL-13
expression (Fig. 5a, b). Lung tissue from WT control mice
increased Muc1 expression in response to dexamethasone
(Fig. 5c). Furthermore, LPS stimulus increased the expres-
sion of Muc1 in WT animals (Fig. 5c). MUC1-KO mice
did not show Muc1 expression in lung tissue confirming
the KO nature (Fig. 5c). GRα expression was not affected
by experimental conditions (Fig. 5d).
Corticosteroids can enhance genes that encode proteins
with anti-inflammatory properties. In this work, dexametha-
sone elevated the expression of corticosteroid-inducible
anti-inflammatory genes MKP1, CRISPLD, CD200, RGS2
and TSC22D3 in lung tissue of WT control animals stimu-
lated with LPS, but not in animals stimulated with LPS +CS
(Fig 6a-e). Furthermore, dexamethasone did not increase
the expression of the anti-inflammatory genes in Muc1 KO
mice (Fig. 6a-e).
Micro-CT-PET image analysis detected an increase of
fludeoxyglucose 18F (18F-FDG) signal expressed as stand-
ard uptake value (SUV) in animals treated with LPS and
LPS + CS (Fig. 7). Dexamethasone decrease SUV values
at 3 mg and 10 mg/kg/day in WT animals stimulated
with LPS, while only dexamethasone 10 mg/kg/day was
effective inhibiting SUV in animals treated with LPS +
CS. In Muc1-KO animals, dexamethasone did not re-
duce SUV values (Fig. 7).
We observed that both LPS and LPS + CS can enhance
the GR phosphorylation at ser226, while dexamethasone
Fig. 3 Cigarette smoke mediates corticosteroid resistance and decreases MUC1 expression in human neutrophils. a Cigarette smoke extract (CSE)
decreased the mRNA gene expression of MUC1 in sputum neutrophils from smokers. b-e Peripheral blood neutrophils from healthy and COPD
patients were stimulated with (b, d) lipopolysaccharide (LPS) or (c, e) with cigarette smoke extract (CSE) during 6 h, and IL-8 and MMP9 levels
were measured by ELISA. f-i Peripheral blood neutrophils form healthy, smokers and COPD patients were incubated with dexamethasone for 1 h
and stimulated with LPS or CSE for 6 h. The results are shown as mean ± SE of n = 4 cell populations from healthy subjects, smokers and COPD
patients. Gene expression was analyzed by real time PCR using the 2-ΔCt as described in methods. Two-way ANOVA followed by Bonferroni post-
hoc tests. a-e *P < 0.05 compared with control/basal; #P < 0.05 compared with healthy group. f-i *P < 0.05 compared with healthy group; #P <
0.05 compared with smoker group
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reduces GR-ser226 expression in lung tissue of WT con-
trol mice (Fig. 8a, b). However, dexamethasone showed
impaired effects reducing GR-ser226 expression in Muc1
KO animals. LPS inflammation, but not LPS + CS, in-
creased the expression of Muc1-CT in lung tissue from
WT control animals (Fig. 8c). Neither LPS nor LPS + CS
modified the Muc1-CT distribution (data not shown).
Furthermore, dexamethasone at the highest dose,
increased the Muc1-CT expression (Fig. 8c). The
anti-inflammatory effects of corticosteroids are partially
mediated by the inhibition of the phosphorylation of dif-
ferent intracellular pathways. Thus, for example, p38
and ERK1/2 phosphorylations are typically enhanced by
LPS and in cells from COPD patients. In this work,
dexamethasone reduced the phosphorylation of p38 and
ERK1/2 at 3 mg and 10 mg/kg/day in WT controls stim-
ulated with LPS, but only at 10 mg/kg/day when it was
stimulated with LPS + CS. In Muc1 KO animals, dexa-
methasone showed lesser effect inhibiting p38 and
ERK1/2 phosphorylation (Fig. 8d-f ).
Confocal immunofluorescence showed a Muc1-
CT-GRα co-localization in the bronchial epithelial cell
cytoplasm of WT mice. The treatment with
dexamethasone induced the bronchial epithelial cell
nuclear translocation of the Muc1-CT-GRα complex
(Fig. 9). In Muc1 KO animals GRα was expressed in
Fig. 4 MUC1 mediates dexamethasone anti-inflammatory effects. a-e Bronchial epithelial Beas2b cells were transiently transfected with siRNA-
MUC1 or with control siRNA(−) for 48 h, incubated with dexamethasone (Dex) for 1 h and (a-d) stimulated with cigarette smoke extract (CSE)
during 24 h. a, b MKP1 and MUC1 mRNA gene expression was analyzed by real time PCR. c, d IL-8 and GM-CSF release was measured by ELISA.
e Glucocorticoid response element (GRE) activation was measured after 4 h of dexamethasone incubation at different concentrations in Beas2b
cells transfected with Cignal GRE Reporter Assay. f Confocal co-immunofluorescence analysis of glucocorticoid alpha (GRα) and MUC1-CT co-
localization in primary human bronchial epithelial cells (HBECs) treated with dexamethasone during 4 h, and in cells incubated with CSE for 24 h
followed by the incubation with dexamethasone for 4 h. DAPI was used to mark cell nuclei. Scale bar: 5 μm. g Protein expression measured by
western blot in HBEC stimulated with CSE during 24 h. h HBECs were incubated with MG132 5 μM during 1 h followed by CSE stimulation
during 24 h. Western blot of different proteins was analysed. i Immunoprecipitation of MUC1-CT and GRα in HBECs stimulated with different
concentrations of CSE. j Immunoprecipitation of MUC1-CT and GRα in HBECs incubated with CSE during 24 h followed by the stimulation with
dexamethasone during 4 h. Representative western blot are showed. The results are shown as mean ± SE of n = 4 independent experiments.
Gene expression was analyzed by real time PCR using the 2-ΔCt as described in methods. One-way ANOVA followed by Bonferroni post-hoc tests.
a, b *P < 0.05 compared with siRNA(−) transfected cells; #P < 0.05 compared with siRNA-MUC1 + Dex group. c, d) *P < 0.05 compared with
siRNA(−) transfected cells; # and ●P < 0.05 compared with siRNA(−) + CSE group; ┴P < 0.05 compared with siRNA(−) + CSE + Dex group. e *P <
0.05 compared with siRNA-MUC1 + Dex group
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bronchial epithelial cell cytoplasm, but nuclear trans-
location in response to dexamethasone was not ob-
served (Fig. 9).
Discussion
The present work shows that the loss of MUC1-CT expres-
sion mediates corticosteroid resistance in in vitro and in
vivo models relevant to the COPD pathology. MUC1-CT
was downregulated in lung tissue, isolated bronchial epithe-
lial cells and neutrophils from heavy smokers and COPD
patients resistant to corticosteroids. Furthermore, cigarette
smoke extract decreased MUC1-CT expression. In vitro
cell MUC1 gene silencing and animal in vivo MUC1 KO
model of COPD inflammation demonstrated that cortico-
steroids mediate part of their anti-inflammatory effects by
forming MUC1-CT-GRα complexes that translocate to the
cell nucleus to increase the expression of anti-inflammatory
genes. These results support previous findings in cortico-
steroid resistant chronic rhinosinusitis with nasal polyps
(CRSwNP) [12] which may be of potential value to
explain, almost in part, the loss of corticosteroid efficacy
in COPD.
Fig. 5 Muc1 KO mice is resistant to the anti-inflammatory effects of dexamethasone in a model of acute cigarette smoke inflammation.
C57BL/6 Muc1 KO mice and WT mice were undergoing intranasal instillation of 75 μg of lipopolysaccharide (LPS) at day 1. Between days
2 and 3, animals were exposed to cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and
5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once
a day between day 1 and 6. Animals were sacrificed at day 6 and lungs were homogenized to analyze the gene mRNA expression of (a)
IL-8, (b) IL-13, (c) Muc1 and (d) GRα. Gene expression was analyzed by real time PCR using the 2-ΔCt as described in methods. Results are
the mean ± SE of n = 8 animals per experimental group. One-way ANOVA followed by Bonferroni post-hoc tests. *P < 0.05 compared with
control. #P < 0.05 compared with LPS. ┴P < 0.05 compared with WT. KO: knock out; WT: wild type; CS: cigarette smoke;
LPS: lipopolysaccharide
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The use of ICS in COPD is currently under debate.
Recent clinical trials using fixed-dose combinations of
LAMA/LABA have demonstrated more effectiveness
than the LAMA or LABA alone in terms of improve-
ment in trough FEV1, transitional dyspnea index (TDI)
and St. George’s Respiratory Questionnaire (SGRQ)
scores [31]. The recent study FLAME showed that the
combination of indacaterol (110 μg) plus glycopyrro-
nium (50 μg) was superior to salmeterol (50 μg) plus flu-
ticasone (500 μg) improving FEV1 and preventing acute
exacerbations of COPD in both moderate and severe
COPD patients [32, 33]. However the LABA/ICS com-
bination or the triple therapy LABA/LAMA/ICS seems
superior in the cases of very severe airflow limitation
[32]. The evidence that dual bronchodilation can prevent
or at least delay the onset of acute exacerbations of
COPD raises the fundamental questions whether it
makes sense to switch all patients from a LABA/ICS
regimen to a LABA/LAMA regimen on the basis of the
improvement in lung function and the lower exacerba-
tion rates [34] or there is a subgroup of patients with
COPD who may benefit the most from this therapy.
Perhaps the nature of COPD exacerbations (viral or bac-
terial) or the inflammatory phenotype (eosinophils vs
neutrophils) could help us to appropriately select the
correct regimen therapy. In this regard, the role of ele-
vated blood eosinophils as a biomarker for the identifica-
tion of candidates for ICS treatment is currently
debated, although recent pooled analysis have ruled out
the association of blood eosinophils as predictor of ICS
good response [35].
Therefore, there is a need to understand the different
cellular and molecular mechanisms implicated in the loss
of corticosteroid efficacy in COPD. A good understanding
of corticosteroid resistance could be of potential value to
design new strategies such as the addition of novel drugs
to reverse corticosteroid resistance [36] or the analysis of
corticosteroid resistance biomarkers to avoid ICS therapy.
Between the different molecular processes associated to
the loss of corticosteroid efficacy, the most analyzed
process involves the activation of phosphatidylinositide
3-kinase (PI3K) δ that switch off histone deacetylase 2
(HDAC2) to avoid the correct GRα-corticosteroid inhib-
ition of NF-kB–dependent inflammatory gene expression
Fig. 6 Corticosteroid anti-inflammatory inducible genes expression is resistant to dexamethasone in Muc1 KO mice. C57BL/6 Muc1 KO mice and
WT mice were undergoing intranasal instillation of 75 μg of lipopolysaccharide (LPS) at day 1. Between days 2 and 3, animals were exposed to
cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and 5, and 10 cigarettes (or control air) at day 6.
Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once a day between day 1 and 6. Animals were sacrificed
at day 6 and lungs were homogenized to analyze the gene mRNA expression of different corticosteroid-inducible genes such as (a) MKP1, (b)
CRISPLD, (c) CD200, (d) RGS2 and (e) TSC22D3. Gene expression was analyzed by real time PCR using the 2-ΔCt as described in methods. Results
are the mean ± SE of n = 8 animals per experimental group. One-way ANOVA followed by Bonferroni post-hoc tests. *P < 0.05 compared with
control. ┴P < 0.05 compared with WT. KO: knock out; WT: wild type; CS: cigarette smoke; LPS: lipopolysaccharide
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[37]. Also, GRα modifications such as the phosphorylation
at specific serine residues of GRα, such as ser226, impedes
nuclear translocation, leading to steroid resistance [38].
The sustained inflammation in COPD is believed to in-
crease and perpetuate the GR-ser226 status [38]. In this re-
gard, the innate immune system through the chronic
stimulation of TLRs activates intracellular p38, ERK1/2
and JNK1 intracellular pathways that can phosphorylate
GRα at ser226 [39, 40]. TLR4 is activated by lipopolysac-
charide (LPS) of gram negative bacteria and cigarette
smoke, and its expression appears to be chronically ele-
vated in bronchial epithelial cells from stable severe and
very severe COPD patients, contributing to airway chronic
inflammation [41]. In this work we confirmed this obser-
vations, showing an increase of TLR4 expression in bron-
chial epithelial cells and neutrophils from heavy smokers
and COPD patients. Unlike TLR4, the expression of
MUC1-CT was decreased in lung tissue, bronchial
epithelial cells and neutrophils from heavy smokers and
COPD patients. Cytoplasmic MUC1-CT mediates
anti-inflammatory effects through the interaction with
TLR signal components [8, 42]. Therefore, the higher ex-
pression of TLR4 and low expression of MUC1-CT impli-
cates a greater inflammatory response. In this work, both,
LPS and CSE promoted a higher inflammatory response
in bronchial epithelial cells and neutrophils from heavy
smokers and COPD patients. Furthermore, bronchial epi-
thelial cells transiently transfected with siRNA-MUC1
showed higher amounts of IL-8 and GM-CSF than siRNA
controls in response to CSE. In this line, Muc1-KO ani-
mals showed higher amount of BAL inflammatory cells
and inflammation, thus confirming the anti-inflammatory
role of MUC1-CT.
In contrast to our findings, recent data indicate that
sputum MUC1 is increased in the acute phase of
COPD exacerbation and also in the BALF of mice
Fig. 7 Muc1 KO mice is resistant to the anti-inflammatory effects of dexamethasone in a model of acute cigarette smoke inflammation analysed
by micro-CT-PET. C57BL/6 Muc1 KO mice and WT mice were undergoing intranasal instillation of 75 μg of lipopolysaccharide (LPS) at day 1.
Between days 2 and 3, animals were exposed to cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4
and 5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once a
day between day 1 and 6. Computed tomography (CT) followed by positron emission tomography (PET) of fludeoxyglucose 18F (18F-FDG) was
measured as standard uptake value (SUV). Representative images are showed. Results are the mean ± SE of n = 8 animals per experimental group.
One-way ANOVA followed by Bonferroni post-hoc tests. *P < 0.05 compared with control. #P < 0.05 compared with LPS/ LPS + CS. KO: knock out;
WT: wild type; CS: cigarette smoke; LPS: lipopolysaccharide
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instilled with intranasal LPS [43]. In this work, intra-
nasal instillation of LPS also increased MUC1 expres-
sion in lung tissue that was abrogated with the
combination of CS. Difference observed could be
explained by the nature of COPD patients studied,
since we analyzed samples from stable COPD and not
from exacerbations that can trigger MUC1 transiently
as anti-inflammatory endogenous control to limit ex-
cessive inflammation [43].
The lack of MUC1-CT not only promoted a higher
inflammation but reduced the anti-inflammatory ef-
fect of corticosteroids. As commented above, the
over-activation of TLR4 in absence of MUC1-CT
could increase the chronic phosphorylation of p38
and ERK1/2 to promote GR-ser226 and consequently
inducing corticosteroid resistance. In this work, dexa-
methasone was unable to inhibit p38 and ERK1/2
phosphorylations in lungs from Muc1 KO mice, thus
allowing sustained and elevated levels of GR-ser226
which has been related with the lack of GRα cell nu-
clear translocation [12]. These data was corroborated
in confocal microscope and immunoprecipitation in
vitro studies using bronchial epithelial cells, showing
nuclear translocation of MUC1-CT-GRα complex
after dexamethasone stimulation that was inhibited
by cigarette smoke pre-incubation. Similar results
were observed in vivo in mice Muc1 KO bronchial
epithelial cells. The interaction of MUC1-CT forming
a complex with GRα has been observed previously in
beas2b bronchial epithelial cells and nasal polyp tis-
sue confirming the results of this study [12]. How-
ever, MUC1-CT can interact with other proteins.
This is the case of the estrogen receptor (ER)-α and
β-catenin that can form complexes with MUC1-CT
to stabilize and protect ERα and β-catenin from their
ubiquitination and degradation allowing nuclear
translocation of both proteins [11, 44]. These find-
ings are in line with a possible protective role of
MUC1-CT on GRα. In this work, the proteasomal
inhibitor MG-132 prevented the CSE-induced
MUC1-CT decrease, suggesting that CSE mediates
MUC1-CT downregulation via proteasomal degrad-
ation. In the same way, proteasomal inhibition re-
duced the GR-ser226 expression, suggesting that
MUC1-CT could protect GRα against phosphoryl-
ation at serine 226.
Corticosteroids mediates part of their anti-inflammatory
effects through the activation of GRE gene regions, thus
Fig. 8 Mechanistic pathways involved in corticosteroid resistance of Muc1 KO mice. C57BL/6 Muc1 KO mice and WT mice were undergoing
intranasal instillation of 75 μg of lipopolysaccharide (LPS) at day 1. Between days 2 and 3, animals were exposed to cigarette smoke (or control
air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and 5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone
at 3 mg/kg/day and 10 mg/kg/day was administered orally once a day between day 1 and 6. Animals were sacrificed at day 6 and lungs were
homogenized to analyze protein expression of (a) glucocorticoid receptor alpha (GRα), (b) GR phosphorylated at ser226 (GR-ser226), (c) Muc1
cytoplasmic tail (CT), (d) phospho-p38 and (e) phopho-ERK1/2. Protein expression was normalized to β-actin. f Representative western blots are
showed. Results are the mean ± SE of n = 8 animals per experimental group. One-way ANOVA followed by Bonferroni post-hoc tests. *P < 0.05
compared with control. #P < 0.05 compared with LPS/ LPS + CS. KO: knock out; WT: wild type; CS: cigarette smoke; LPS: lipopolysaccharide
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increasing the expression of corticosteroid dependent
anti-inflammatory genes. In this work, bronchial epithelial
cells transfected with siRNA-MUC1 showed an impaired
GRE activation in response to growing concentrations of
dexamethasone that was translated in a lack of expression
of corticosteroid inducible anti-inflammatory MKP1 gene.
Similar findings were observed in Muc1 KO mice, in
which corticosteroid-inducible anti-inflammatory
genes MKP1, CRISPLD, CD200, RGS2 and TSC22D3
were resistant to dexamethasone. Interestingly, WT
control animals stimulated with LPS and CS were
also resistant to the effect of dexamethasone increas-
ing anti-inflammatory genes and inhibiting inflamma-
tory cytokines such as IL8 and IL13 which related
CS with resistance to corticosteroids as previously
outlined [4].
However, although the findings of this study provide
a rational explanation for the lack of efficacy of corti-
costeroids in patients with COPD, other mechanisms
may also be implicated [37], thus sharing different
mechanisms that can contribute to the final COPD
phenotype.
Conclusions
We have demonstrated a new role for MUC1-CT in
the modulation of the anti-inflammatory effects of
corticosteroids in COPD. Our findings suggest a
possible explanation for why corticosteroids cannot
repress inflammation in COPD, thus contributing to
the amount of knowledge of corticosteroid resistance
processes in COPD which may be of potential value
to develop new strategies to the COPD treatment.
Fig. 9 Dexamethasone induces Muc1-CT nuclear translocation and co-localization with GRα in bronchial epithelium of WT mice but not in
MUC1 KO mice. C57BL/6 Muc1 KO mice and WT mice were undergoing dexamethasone 10 mg/kg/day (orally) for 6 days. Animals were
sacrificed at day 6 and lungs were fixed in paraformaldehyde (4%) for 48 h and embedded in Tissue-Tek® OCT™ cryosectioning
compound. Lung slices were immunostained with MUC1-cytoplasmic tail (CT) and glucocorticoid receptor alpha (GRα) antibodies with
rhodamine/fluorescein secondary antibodies. DAPI was used to mark cell nucleus. Representative con-focal images are showed. Scale
bar: 5 μm
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